← Arcutis Biotherapeutics, Inc. (ARQT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Arcutis Biotherapeutics, Inc. (ARQT)
Pharmaceutical Preparations · market cap $3.3B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-27 (est.)
Earnings
Pipeline
19
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Arcutis Biotherapeutics (ARQT) is a commercial-stage dermatology company built around topical roflumilast, a PDE4 inhibitor formulated across multiple concentrations and vehicles targeting psoriasis, atopic dermatitis, and seborrheic dermatitis. The company received a positive PDUFA outcome on 2026-06-20, clearing a meaningful regulatory hurdle, and has rapidly scaled revenue from $4M in 2022 to $376M in 2025. With a $3.4B market cap, $34.8M cash, and $82.6M net debt, Arcutis is at an inflection point between commercial momentum and balance sheet constraint.
The catalyst path
- 2026-10-27 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Roflumilast Cream 0.3% | Phase 2 | Plaque Psoriasis |
| Topical roflumilast | Phase 3 | Chronic Plaque Psoriasis |
| ARQ-252 cream 0.3% | Phase 2 | Chronic Hand Eczema |
| ARQ-151 Active | Phase 3 | Atopic Dermatitis Eczema |
| Roflumilast Cream 0.15% | Phase 3 | Atopic Dermatitis Eczema |
| Roflumilast Cream 0.05% | Phase 3 | Atopic Dermatitis |
| ARQ-151 cream 0.5% | Phase 2 | Psoriasis |
| ARQ-151 cream 0.05% | Phase 2 | Atopic Dermatitis (Eczema) |
| ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Phase 3 | Atopic Dermatitis Eczema |
| ARQ-151 cream 0.3% | Phase 2 | Psoriasis |
| Roflumilast 0.3% cream | Phase 3 | Chronic Plaque Psoriasis |
| Roflumilast | Phase 2 | Plaque Psoriasis |
| Roflumilast Foam 0.3% | Phase 3 | Scalp Psoriasis |
| ARQ-154 | Phase 2 | Seborrheic Dermatitis |
| ARQ-151 0.3% cream | Phase 3 | Chronic Plaque Psoriasis |
| Roflumilast Foam | Phase 3 | Seborrheic Dermatitis |
| Roflumilast Cream | Phase 3 | Atopic Dermatitis Eczema |
| Topical roflumilast 0.3% foam | Phase 2 | Hidradenitis Suppurativa |
| Roflumilast topical 0.3% foam | Phase 2 | Non-segmental Vitiligo |
Price & technical context
3-month
+2.3%
6-month
+12.2%
12-month
+41.9%
52-wk range
$18.85–$31.20
vs 50-day MA
+2.5%
vs 200-day MA
+4.7%
Realized vol
55.9%
Max drawdown
-37.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ARQT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.